Clinical trial
An External Control, Observational, Retrospective Study Assessing the Effect of Pralsetinib Compared With Best Available Therapy for Patients With RET-Fusion Positive Advanced Non-Small Cell Lung Cancer
NCT04697446 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An External Control, Observational, Retrospective Study Assessing the Effect of Pralsetinib Compared With Best Available Therapy for Patients With RET-Fusion Positive Advanced Non-Small Cell Lung Cancer
- Lead sponsor
- Blueprint Medicines Corporation
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- December 1, 2020
- Completion date
- October 31, 2021
- Enrollment
- 279 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
bronchial diseases, carcinoma, carcinoma, bronchogenic, carcinoma, non-small-cell lung, head and neck neoplasms, lung diseases, lung neoplasm, metastatic non small cell lung cancer, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, germ cell and embryonal, neoplasms, nerve tissue, respiratory tract diseases, respiratory tract neoplasms, ret-fusion non small cell lung cancer, thoracic neoplasms